Edition:
United Kingdom

People: AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

8.99USD
14 Jun 2019
Change (% chg)

$-0.30 (-3.23%)
Prev Close
$9.29
Open
$9.28
Day's High
$9.30
Day's Low
$8.86
Volume
194,681
Avg. Vol
237,669
52-wk High
$26.08
52-wk Low
$8.86

Santini, Gino 

Mr. Gino Santini is Independent Chairman of the Board of the Company. He has been a director since February 2012 and has served as Chairman of the Board of Directors since April 2014. From 1983 to 2010, Mr. Santini held a variety of commercial and operational roles at Eli Lilly and Company (“Eli Lilly”), a public pharmaceutical company, serving most recently from 2007 to 2010 as Senior Vice President, Corporate Strategy and Business Development, where he led corporate strategy and long-range planning, mergers and acquisitions, new product licensing and the expansion of Lilly Ventures in the U.S. and China. During his tenure at Eli Lilly, Mr. Santini held various leadership positions of increasing responsibility, including manager of various international regions, Senior Vice President of Corporate Strategy and Policy from 2004 to 2007, President of U.S. operations from 1999 to 2004 and President of the women’s health franchise from 1997 to 1999. Mr. Santini has served on the Board of Directors of Collegium Pharmaceuticals, Inc., a public pharmaceutical company, since 2012, where he is the chair of the Compliance Committee and a member of the Compensation Committee. Mr. Santini has also served on the Board of Directors of Allena Pharmaceuticals, Inc., a public specialty pharmaceutical company, since 2012 where he is the chair of the Compensation Committee and a member of the Audit Committee. Since December 2015, Mr. Santini has served on the Board of Directors of Intercept Pharmaceuticals, Inc. a public biopharmaceutical company, where he is also the chair of the Compensation Committee and a member of the Audit Committee. Mr. Santini also serves on the Board of Directors, as well as the Chair of the Transactions Committee and a member of the Compensation Committee of the Board of Directors, of Horizon Pharma, Plc., a public biopharmaceutical company, where he has been a director since 2012. Mr. Santini has served on the Board of Directors of Intarcia Therapeutics, Inc., a biopharmaceutical company, since 2013.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 87,482
Long-Term Incentive Plans, USD --
All Other, USD 195,499
Fiscal Year Total, USD 282,981

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Gino Santini

282,981

William Heiden

4,966,220

Edward Myles

1,537,340

Elizabeth Bolgiano

--

Joseph Vittiglio

1,203,710

J. Alan Butcher

2,083,060
As Of  31 Dec 2018